Cost analysis backs immediate access to agonist drugs for opioid dependence

November 29, 2017 Gary Enos

Gary A. Enos, Contributing Editor

A cost-effectiveness analysis using California data makes a strong case for significant public investment in methadone and buprenorphine treatment.

Previous Article
Doctors make big money testing urine for drugs, then ignore abnormal results

Kaiser Health NewsIn nearly a dozen recent criminal cases, prosecutors have cited evidence that doctors sup...

Next Article
Integrated care: a beloved platitude

Ed Jones, PhDIntegrated care is a slogan. It seems like a high principle, but it is really a ruse or gross ...


Have Behavioral Health Business updates sent to your inbox today!

First Name
Last Name
Thank you!
Error - something went wrong!